{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:03:09Z","timestamp":1788314589412,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejca.2023.113442","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T05:31:50Z","timestamp":1700199110000},"page":"113442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Lineage-specific regulation of PD-1 expression in early-stage hepatocellular carcinoma following 90yttrium transarterial radioembolization \u2013 Implications in treatment outcomes"],"prefix":"10.1016","volume":"196","author":[{"given":"Kelley G.","family":"N\u00fa\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Sandow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Gimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0515-3764","authenticated-orcid":false,"given":"Mina","family":"Hibino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T.","family":"Thevenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ejca.2023.113442_bib1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2023.113442_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejca.2023.113442_bib3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jamcollsurg.2006.06.016","article-title":"Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival","volume":"203","author":"Bharat","year":"2006","journal-title":"J Am Coll Surg"},{"issue":"1","key":"10.1016\/j.ejca.2023.113442_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejca.2023.113442_bib5","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.23944","article-title":"Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival","volume":"52","author":"Hilgard","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2023.113442_bib6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fonc.2014.00120","article-title":"Yttrium-90 radioembolization of hepatic metastases from colorectal cancer","volume":"4","author":"Raval","year":"2014","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2023.113442_bib7","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.31318","article-title":"Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort","volume":"73","author":"Gabr","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejca.2023.113442_bib8","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.29691","article-title":"Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience","volume":"68","author":"Salem","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejca.2023.113442_bib9","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ejca.2023.113442_bib10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113442_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.ejca.2023.113442_bib12","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00262-021-03087-z","article-title":"PD-1 expression in hepatocellular carcinoma predicts liver-directed therapy response and bridge-to-transplant survival","volume":"71","author":"Nunez","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.ejca.2023.113442_bib13","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ejca.2023.113442_bib14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ejca.2023.113442_bib15","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1148\/radiol.2017170731","article-title":"Assessment of Response to Transcatheter Arterial Chemoembolization with Doxorubicin-eluting Microspheres: Tumor Biology and Hepatocellular Carcinoma Recurrence in a 5-year Transplant Cohort","volume":"286","author":"Sandow","year":"2018","journal-title":"Radiology"},{"issue":"12","key":"10.1016\/j.ejca.2023.113442_bib16","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.jvir.2015.08.015","article-title":"Role of Locoregional Therapy and Predictors for Dropout in Patients with Hepatocellular Carcinoma Listed for Liver Transplantation","volume":"26","author":"Sheth","year":"2015","journal-title":"J Vasc Inter Radio"},{"issue":"2 Suppl 1","key":"10.1016\/j.ejca.2023.113442_bib17","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1002\/lt.20036","article-title":"Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients","volume":"10","author":"Carr","year":"2004","journal-title":"Liver Transpl"},{"issue":"12","key":"10.1016\/j.ejca.2023.113442_bib18","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1097\/01.RVI.0000184594.01661.81","article-title":"Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival","volume":"16","author":"Salem","year":"2005","journal-title":"J Vasc Inter Radio"},{"issue":"2","key":"10.1016\/j.ejca.2023.113442_bib19","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/gutjnl-2021-326869","article-title":"Y(90)-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers","volume":"72","author":"Rivoltini","year":"2023","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ejca.2023.113442_bib20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/j.gastro.2022.09.005","article-title":"Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma","volume":"164","author":"Haber","year":"2023","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ejca.2023.113442_bib21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: Performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.ejca.2023.113442_bib22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2023.113442_bib23","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.27752","article-title":"Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria","volume":"61","author":"Yao","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejca.2023.113442_bib24","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jhep.2022.01.002","article-title":"The updated BCLC staging system needs further refinement: A surgeon's perspective","volume":"76","author":"Xu","year":"2022","journal-title":"J Hepatol"},{"issue":"19","key":"10.1016\/j.ejca.2023.113442_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194765","article-title":"Baseline Alpha-Fetoprotein, Alpha-Fetoprotein-L3, and Des-Gamma-Carboxy Prothrombin Biomarker Status in Bridge to Liver Transplant Outcomes for Hepatocellular Carcinoma","volume":"13","author":"Nunez","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10088","key":"10.1016\/j.ejca.2023.113442_bib26","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2023.113442_bib27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3389\/fonc.2014.00198","article-title":"Side effects of yttrium-90 radioembolization","volume":"4","author":"Riaz","year":"2014","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.113442_bib28","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1053\/j.gastro.2018.08.030","article-title":"Association Between Expression Level of PD1 by Tumor-Infiltrating CD8(+) T Cells and Features of Hepatocellular Carcinoma.","volume":"155","author":"Kim","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ejca.2023.113442_bib29","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/1754-9485.13405","article-title":"Immunotherapy and Transarterial therapy of HCC: What the interventional radiologist needs to know about the changing landscape of HCC treatment?","volume":"66","author":"Tibballs","year":"2022","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2023.113442_bib30","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.113442_bib31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","article-title":"Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma","volume":"68","author":"Chew","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ejca.2023.113442_bib32","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-6613-1","article-title":"Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy","volume":"20","author":"Craciun","year":"2020","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2023.113442_bib33","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","article-title":"A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study","volume":"49","author":"Lam","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2023.113442_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/JHC.S350219","article-title":"Dynamic Lymphocyte Changes Following Transarterial Radioembolization: Association with Normal Liver Dose and Effect on Overall Survival","volume":"9","author":"Young","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"issue":"12","key":"10.1016\/j.ejca.2023.113442_bib35","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.jvir.2019.08.001","article-title":"Neutrophil\/Lymphocyte ratio predicts increased risk of immediate progressive disease following chemoembolization of hepatocellular carcinoma","volume":"30","author":"Cruz","year":"2019","journal-title":"J Vasc Inter Radio"},{"issue":"5","key":"10.1016\/j.ejca.2023.113442_bib36","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.hpb.2017.01.013","article-title":"Neutrophil to lymphocyte ratio predicts disease progression following intra-arterial therapy of hepatocellular carcinoma","volume":"19","author":"Taussig","year":"2017","journal-title":"HPB (Oxf)"},{"issue":"8","key":"10.1016\/j.ejca.2023.113442_bib37","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1007\/s00259-020-05186-y","article-title":"Prognostic significance of neutrophil to lymphocyte ratio dynamics in patients with hepatocellular carcinoma treated with radioembolization using glass microspheres","volume":"48","author":"Li","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2023.113442_bib38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/JHC.S282062","article-title":"Radiation-associated lymphopenia and outcomes of patients with unresectable hepatocellular carcinoma treated with radiotherapy","volume":"8","author":"De","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.ejca.2023.113442_bib39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fonc.2012.00119","article-title":"T lymphocytes and normal tissue responses to radiation","volume":"2","author":"Schaue","year":"2012","journal-title":"Front Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300744X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300744X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:26Z","timestamp":1760733746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492300744X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":39,"alternative-id":["S095980492300744X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113442","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lineage-specific regulation of PD-1 expression in early-stage hepatocellular carcinoma following 90yttrium transarterial radioembolization \u2013 Implications in treatment outcomes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113442"}}